MedTrace Logo

CVL006 Combination Therapy in Advanced Solid Tumors

NCT07157956 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 318

Last updated 2025-09-05

No results posted yet for this study

Summary

This study is a multi-center, open-label, dose-escalation and dose-optimized phase I/II clinical trial. Objective: To determine the safety, tolerability, PK characteristics and preliminary efficacy data of CVL006 combined with pemetrexed + carboplatin/SKB264/ DS-8201a/ Enfortumab Vedotin in patients with advanced solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

CVL006 combined with pemetrexed and carboplatin

CVL006 combined with pemetrexed and carboplatin

DRUG

CVL006 in combination with SKB264

CVL006 in combination with SKB264

DRUG

CVL006 in combination with DS-8201

CVL006 in combination with DS-8201

DRUG

CVL006 in combination with Enfortumab Vedotin

CVL006 in combination with Enfortumab Vedotin

Sponsors & Collaborators

  • Convalife (Shanghai) Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Li Zhang · Sun Yat-sen University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-10
Primary Completion
2028-08-12
Completion
2028-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07157956 on ClinicalTrials.gov